1. Chapter 61: Transplantation Osteoporosis
Peter R. Ebeling

2. Table 1. Risk Factors for Post-Transplant Bone Loss and Fractures
From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.
Table 1. Risk Factors for Post-Transplant Bone Loss and Fractures
© 2008 American Society for Bone and Mineral Research

3. From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.
Figure 1
Figure 1 Mean percentage changes in (A) lumbar spine BMD, (B) femoral neck BMD, and (C) total hip BMD (±SE) for each treatment group at each assessment time. The p values refer to the outcome of a t-test comparing the two treatment groups (no pamidronate vs. pamidronate) at each assessment time. (Reproduced with permission from Grigg A, Shuttleworth P, Reynolds J, Schwarer A, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling P 2006 Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Endocrinol Metab 91:3835–3843, Copyright 2006, The Endocrine Society.)
Figure 1 Mean percentage changes in (A) lumbar spine BMD, (B) femoral neck BMD, and (C) total hip BMD (±SE) for each treatment group at each assessment time. The p values refer to the outcome of a t-test comparing the two treatment groups (no pamidronate vs. pamidronate) at each assessment time. (Reproduced with permission from Grigg A, Shuttleworth P, Reynolds J, Schwarer A, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling P 2006 Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Endocrinol Metab 91:3835–3843, Copyright 2006, The Endocrine Society.)